目的研究原发性肝癌雌激素受体（ＥＲ）的表达及内分泌治疗的临床价值．方法应用Ｌｅｅ氏荧光配体细胞化学法检测４１例手术病理确诊的原发性肝癌ＥＲ的表达．本组男３８例，女３例，年龄２５岁～７２岁．同时检测肝癌的组织类型、分化程度、肿瘤大小、血清ＡＦＰ及ＣＥＡ．６例ＥＲ阳性者采用他莫昔芬治疗（每次２０ｍｇ，２次／ｄ，长期服用）并观察疗效．结果肝癌组织ＥＲ阳性２０／４１例，阳性率４８８％．ＥＲ阳性率与患者年龄、性别、ＡＦＰ、ＣＥＡ含量及组织类型（梁状型ＥＲ阳性４５０％，腺样型３３３％，实体型７１４％，硬化型６６７％，透明细胞型２５０％；Ｐ＞００５）无明显关系，与肿瘤体积（≥１０ｃｍ，ＥＲ阳性率７５０％；＜１０ｃｍ，ＥＲ阳性２３８％；Ｐ＜００１）和分化程度（分化好２６例，ＥＲ阳性３４６％；分化差１５例，ＥＲ阳性７３３％；Ｐ＜００５）有显著关系．本组ＥＲ阳性病例中６例经他莫昔芬内分泌治疗有效５／６（８３３％），其中４例ＡＦＰ下降．结论ＥＲ阳性肝细胞癌患者进行内分泌治疗有一定疗效 5. Objective To study the clinical value of estrogen receptor (ER) expression and endocrine therapy in primary liver cancer. Methods The expression of ER in 41 cases of primary hepatic carcinoma confirmed by pathology was detected by Lee’s fluorescence ligand cytochemistry. The group of 38 males and 3 females, aged 25 to 72 years old. At the same time, the histological type, differentiation, tumor size, serum AFP and CEA were detected. 6 cases of ER-positive were treated with tamoxifen (20mg each time, 2 times / d, long-term use) and observed efficacy. Results The positive rate of ER was 20/41, and the positive rate was 48.8%. ER positive rate and patient age, gender, AFP, CEA content and tissue type (beam-type ER-positive 45  0%, adenoid type 33  3%, solid type 71  4%, hardening type 66  7%, transparent Cell type 250%; P>005) No significant relationship with tumor volume (≥10cm, ER positive rate 750%; <10cm, ER positive 238%; P<001) and differentiation The degree (differentiated well in 26 cases, ER positive 34  6%; poor differentiation in 15 cases, ER positive 73  3%; P <0  05) had a significant relationship. Of the ER-positive cases in this group, 6 cases were treated with Tamoxifen endocrine therapy 5/6 (83. 3%), of which 4 cases of AFP decreased. Conclusions Endocrine therapy is effective in patients with ER-positive hepatocellular carcinoma